Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Globus Medical, Inc. Class A Common Stock (NY:GMED)

59.57 +1.00 (+1.71%)
Streaming Delayed Price Updated: 2:03 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Globus Medical, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
Winners And Losers Of Q2: Globus Medical (NYSE:GMED) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including Globus Medical (NYSE:GMED) and its peers. 
Via StockStory
3 Cash-Producing Stocks Worth Your Attention
Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions. 
Via StockStory
1 Cash-Heavy Stock with Exciting Potential and 2 That Underwhelm
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
Earnings Scheduled For August 7, 2025
 
Via Benzinga
How Is The Market Feeling About Globus Medical?
 
Via Benzinga
Price Over Earnings Overview: Globus Medical
 
Via Benzinga
2 Reasons to Watch GMED and 1 to Stay Cautious
Globus Medical’s stock price has taken a beating over the past six months, shedding 21.5% of its value and falling to $57.60 per share. This may have investors wondering how to approach the situation. 
Via StockStory
Topics Government World Trade
Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might
The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
2 of Wall Street’s Favorite Stocks with Promising Prospects and 1 We Question
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
1 Small-Cap Stock with Solid Fundamentals and 2 Facing Headwinds
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
Sherwin-Williams, Sealed Air, Super Micro, Globus Medical, and Haemonetics Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested... 
Via StockStory
Topics ETFs Economy
Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage
Carlsmed secures NTAP reimbursement and FDA support, while BofA projects strong revenue growth and assigns a Buy rating with a $16 target. 
Via Benzinga
Globus Medical Inc - A (NYSE:GMED): A Prime Example of Affordable Growth with Strong Fundamentals
Globus Medical (GMED) exemplifies Affordable Growth investing with strong revenue/earnings growth, reasonable valuation, and solid profitability—ideal for GARP-focused investors. 
Via Chartmill
1 Cash-Producing Stock Worth Your Attention and 2 We Find Risky
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
Inspire Medical Systems, UFP Technologies, Globus Medical, Neogen, and Dentsply Sirona Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. 
Via StockStory
Topics Bonds Economy Stocks
GMED Q2 Deep Dive: New CEO, Nevro Integration, and Product Pipeline Propel Growth
Medical device company Globus Medical (NYSE:GMED) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 18.4% year on year to $745.3 million. The company expects the full... 
Via StockStory
Topics Economy
Globus Medical (GMED) Shares Skyrocket, What You Need To Know
Shares of medical device company Globus Medical (NYSE:GMED) jumped 5.1% in the morning session after the company reported strong second-quarter financial results that surpassed Wall Street's... 
Via StockStory
Globus Medical (NYSE:GMED) Exceeds Q2 Expectations
Medical device company Globus Medical (NYSE:GMED) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 18.4% year on year to $745.3 million. The company expects the full year’s revenue... 
Via StockStory
Globus Medical (GMED) Q2 Revenue Up 18%
Via The Motley Fool
Globus Medical Inc - A (NYSE:GMED): A Strong Growth Stock with a Promising Technical Setup
Globus Medical (GMED) combines strong fundamentals—32% revenue growth, solid profitability, and zero debt—with a technical setup hinting at a potential breakout. A growth stock worth watching. 
Via Chartmill
Globus Medical (GMED) Q2 Earnings: What To Expect
Medical device company Globus Medical (NYSE:GMED) will be reporting results this Thursday after market hours. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence World Trade
1 Safe-and-Steady Stock Worth Investigating and 2 We Find Risky
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
Topics Supply Chain
Globus Medical Inc - A (NYSE:GMED): A Strong GARP Candidate with Solid Growth and Fair Valuation
Globus Medical (GMED) offers strong growth, solid profitability, and fair valuation, making it an ideal GARP strategy pick for investors seeking balanced returns. 
Via Chartmill
Why Globus Medical (GMED) Shares Are Trading Lower Today
Shares of medical device company Globus Medical (NYSE:GMED) fell 6.6% in the afternoon session after the unexpected resignation of its President and CEO, Daniel Scavilla. 
Via StockStory
Topics Government World Trade
2 Oversold Stocks Set for a Comeback and 1 to Ignore
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds. 
Via StockStory
4 Analysts Assess Globus Medical: What You Need To Know
 
Via Benzinga
GLOBUS MEDICAL INC - A (NYSE:GMED) – A Strong Growth Stock with Technical Breakout Potential
Globus Medical (NYSE:GMED) is a strong growth stock with solid fundamentals and a potential technical breakout, making it a candidate for investors seeking growth opportunities in the healthcare... 
Via Chartmill
GLOBUS MEDICAL INC - A (NYSE:GMED) – A Strong Growth Stock with Reasonable Valuation
Globus Medical (NYSE:GMED) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth in the healthcare sector. 
Via Chartmill
2 Reasons to Watch GMED and 1 to Stay Cautious
Shareholders of Globus Medical would probably like to forget the past six months even happened. The stock dropped 28.9% and now trades at $58.14. This was partly due to its softer quarterly results and... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.